In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Juno Therapeutics GmbH

Division of Celgene Corp.
www.stage-celltherapeutics.com

Latest From Juno Therapeutics GmbH

Regen Medicine Drives Big Uptick In 2015 Start-Up Dealmaking

Biotech start-ups cut deals at a rapid pace in 2015, signing almost twice the number of alliances done in 2014. Regenerative medicine was prominent in key partnerships.

BioPharmaceutical Deals

Start-Up Quarterly Statistics, Q2 2015

Life sciences start-ups raised $2.61 billion in Q2 2015. Biotechs penned 38 alliances; seven acquisitions were signed, none in the medical device industry.

BioPharmaceutical Medical Device

Biopharma Quarterly Dealmaking Statistics, Q2 2015

Q2 biopharma financing reached $15.4 billion, a slight increase over the previous quarter; leading the M&A activity was CVS' $11.8 billion buy of Omnicare; and AstraZeneca and Juno were the two most active dealmakers in cancer immunotherapy, a popular therapeutic focus of Q2 alliances.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, June 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Stage Cell Therapeutics GMBH
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Celgene Corp.
  • Senior Management
  • Herbert Stadler, PhD, CEO
    Lothar Germeroth, PhD, COO
  • Contact Info
  • Juno Therapeutics GmbH
    Phone: 551 506 72 111
    Rudolf-Wissell-Str. 28
    Gottingen, D-37079
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register